Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Growth in Short Interest

Atossa Therapeutics, Inc. (NASDAQ:ATOS) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,250,000 shares, an increase of 5.8% from the January 15th total of 8,740,000 shares. Based on an average trading volume of 876,500 shares, the short-interest ratio is currently 10.6 days.

Atossa Therapeutics Stock Performance

Shares of NASDAQ:ATOS opened at $0.83 on Monday. The firm has a market capitalization of $104.44 million, a P/E ratio of -3.77 and a beta of 1.24. The stock has a 50 day moving average price of $0.94 and a 200-day moving average price of $1.22. Atossa Therapeutics has a 52-week low of $0.72 and a 52-week high of $2.31.

Institutional Trading of Atossa Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATOS. Renaissance Technologies LLC grew its stake in shares of Atossa Therapeutics by 18.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock worth $1,471,000 after buying an additional 247,562 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atossa Therapeutics by 141.4% in the 4th quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock worth $341,000 after buying an additional 211,654 shares during the last quarter. Virtu Financial LLC grew its stake in shares of Atossa Therapeutics by 311.1% in the 4th quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock worth $197,000 after buying an additional 157,549 shares during the last quarter. Barclays PLC grew its stake in shares of Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after buying an additional 123,683 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Atossa Therapeutics by 7.5% in the 4th quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock worth $968,000 after buying an additional 71,525 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ATOS. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday, January 30th. Finally, Ascendiant Capital Markets upped their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.